Cycle on Jun 13, 2026

I will start by listing the open threads and watches for this topic to see what specific questions or triggers need attention.

I will retrieve the current notes to see what we have already covered and what slugs are active.

The current date is June 13, 2026. Let's do some searches for recent science, health, space, biology, and drug developments from the past few days (since June 10-13, 2026). I will search for on-topic news to see what is new. I'll search with `sort="recent"` and `freshness="week"`. Let's look for clinical trials, FDA approvals, space, disease outbreaks, etc. I'll start by searching for any fresh health or science news. Let's do `web_search` with recent-focused queries. Let's look for "FDA approval", "Phase 3 clinical trial", "Ebola", "ISS", "outbreak", "WHO", "CDC", "space", "breakthrough". Let's run a few queries. First, let's look for any recent FDA approvals or clinical trial readouts this week. Let's search for "FDA approval" or similar phrases in the last week. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will run a search for recent FDA approvals and regulatory announcements from this week.

Wow, this is an incredible batch of news! Let's list some of the major headlines that just surfaced in the last few hours/days (around June 13-14, 2026): 1. FDA approves bemotrizinol (PARSOL Shield by DSM-Firmenich) - the first new sunscreen ingredient approved in the US in 20 years! 2. FDA approves Axsome's Auvelity (dextromethorphan/bupropion) for Alzheimer's disease agitation, based on Phase 3 ADVANCE-1 and ACCORD-2. 3. FDA grants expanded/accelerated approval for Sanofi's Tzield (teplizumab) in Stage 3 Type 1 diabetes (it was previously approved for delaying Stage 3 in Stage 2, now approved for Stage 3 Type 1 diabetes!). Let's verify this. 4. FDA approves AstraZeneca's Truqap (capivasertib) in combination with abiraterone and prednisone (likely in prostate cancer, let's verify). 5. Guardant Health announces FDA approval of Guardant360 CDx as companion diagnostic for Boehringer Ingelheim's HERNEXEOS. 6. FDA issues emergency approval for a drug to treat screwworms in pets (as US screwworm cases rise). Let's do some more searches to get the exact details of these approvals, since they are highly consequential health and drug regulatory actions that happened in the past 24-48 hours. Let's first search for "bemotrizinol FDA approval" or "FDA expands sunscreen options". This is a huge milestone since US sunscreen filters have been notoriously outdated compared to Europe. Let's search about "bemotrizinol FDA approval" to find the press release or official announcement. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will search for the FDA's press release and details on the bemotrizinol sunscreen approval.

This is a major story: the FDA approved bemotrizinol, the first new sunscreen chemical filter approved in the US in over 20 years (or since 1996/1999 depending on the source). Let's fetch a couple of these articles to get precise quotes and technical details (such as photostability, UVA/UVB broad-spectrum, brand name Parsol Shield, DSM-Firmenich, and the 18-month marketing exclusivity). Let's fetch the CNN or NYT or FDA press release or NPR article. I will fetch the CNN article and the FDA press release or NPR. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will fetch the CNN article to get detailed quotes and background on the bemotrizinol approval.

This is a spectacular update for diabetes care! On Friday, June 12, 2026, the FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged 8 to 17 with newly diagnosed Stage 3 (clinical) Type 1 diabetes. This is a massive expansion from its previous indication (which was to delay the onset of Stage 3 in patients with Stage 2 T1D). Let's fetch the Globenewswire or STAT News article to get exact details, quotes, and trial evidence. Let's fetch the STAT News article first. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will fetch the STAT News article on Tzield's expanded approval to get the clinical trial details and quotes.

Let's fetch the Sanofi press release on the Tzield approval for Stage 3 T1D (from June 12, 2026). It contains the key details of the PROTECT Phase 3 study, which served as the clinical basis for this accelerated approval. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will fetch the Sanofi official press release on Tzield's accelerated approval in Stage 3 Type 1 diabetes.

This is a massive development. It marks the first disease-modifying therapy for patients *recently diagnosed* with Stage 3 T1D, meaning it can preserve beta-cell function (assessed by C-peptide) during the "honeymoon" period right after clinical diagnosis. This is an accelerated approval based on the Phase 3 PROTECT trial, and the confirmatory Phase 3 trial is called BETA-PRESERVE (NCT07088068), which is currently enrolling. Wait, let's look at the other approvals and trial readouts that we found in the first search. 1. Axsome's Auvelity received FDA approval to treat Alzheimer's disease agitation (ADVANCE-1 and ACCORD-2 Phase 3 trials). Let's search for this to get details! 2. AstraZeneca's Truqap (capivasertib) combination approved in the US (we saw "Truqap combo wins new approval in the USA" with abiraterone and prednisone). Let's search for this. 3. Guardant360 CDx companion diagnostic approval for Boehringer Ingelheim's HERNEXEOS. 4. Emergency approval of a pet screwworm drug. Let's do a search on Axsome's Auvelity for Alzheimer's agitation. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will search for Axsome's Auvelity FDA approval for Alzheimer's agitation.

Ah, let's look for the exact date of Axsome's Auvelity approval for Alzheimer's agitation. It seems it happened recently, let's search for "Axsome Therapeutics announces FDA approval of Auvelity" and check the date. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will search for the official press release of Axsome's Auvelity approval for Alzheimer's agitation to confirm the date and clinical details.

Ah! The Auvelity approval for Alzheimer's agitation actually occurred on April 30, 2026. This is not a new approval from this week, although it's mentioned in a recent review of the pipeline. Since it occurred in April, it's not "brand new" for this cycle. Let's check the other approval: AstraZeneca's Truqap (capivasertib). Let's search "AstraZeneca Truqap FDA approval 2026" or "capivasertib abiraterone 2026". Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will search for the details of AstraZeneca's Truqap (capivasertib) combination approval.

Excellent! On June 12, 2026, the FDA approved AstraZeneca's Truqap (capivasertib) in combination with abiraterone and prednisone for adult patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). This is based on the Phase 3 CAPItello-281 trial. Let's fetch the AstraZeneca press release or a detailed article to get exact quotes and stats (like PFS or risk reduction, hazard ratio, and key details). Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will fetch the AstraZeneca press release on Truqap's FDA approval to get the clinical trial data and hazard ratios.

This is an excellent, detailed source! The Truqap (capivasertib) combination approval is based on the CAPItello-281 Phase III trial, which showed a statistically significant 19% reduction in risk of radiographic disease progression or death, and improved median rPFS by 7.5 months (33.2 months vs 25.7 months, HR 0.81, p=0.034). This is a first-in-class AKT inhibitor. It was approved on June 12, 2026. Let's check if there are other fresh stories. Let's look for "screwworm pets" and "Guardant360 CDx HERNEXEOS". Let's search "screwworm pets FDA emergency approval" first. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will search for the details of the FDA emergency approval for a pet screwworm treatment.

This is another extremely interesting and consequential public health/veterinary/outbreak story. Let's fetch the Reuters or Forbes article on the screwworm outbreak and FDA's emergency authorization of nitenpyram (generic OTC tablet) for dogs and cats. Wait, New World Screwworm (NWS) is a devastating parasite that hasn't been in the US in decades (except for an outbreak in the Florida Keys in 2016). Now there are multiple cases confirmed in Texas and New Mexico (nine cases confirmed as of June 11, 2026, including livestock in Texas and a dog in New Mexico). It's causing a major One Health response. Let's fetch the Forbes or CBS News article to understand the details. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will fetch the Forbes article on the screwworm outbreak to understand the situation, including the case counts, the generic drug authorized, and the policy context.

This is an absolutely fascinating, high-consequence public health and agricultural policy story. Let's synthesize the key aspects of the New World Screwworm (NWS) outbreak: - What is it? A flesh-eating parasite (*Cochliomyia hominivorax*) that was eradicated from the US in the 1960s. - Current situation: A major outbreak has re-emerged in the US southwest. As of June 11, 2026, cases have risen to 9 confirmed cases (or 7, 9 is mentioned by AVMA as of June 11: "Nine U.S. cases of New World screwworm (NWS) have been confirmed by the U.S. Department of Agriculture (USDA) Animal and Plant..."). The cases are in cattle, goats, and a dog in Texas and New Mexico. First discovered in May 2026 in a 3-week-old calf in La Pryor, Texas near the Mexico border. - FDA response: On June 11, 2026, the FDA issued an Emergency Use Authorization (EUA) for generic **nitenpyram** tablets (an oral drug typically used to treat fleas) to treat New World screwworm infestations in dogs, puppies, cats, and kittens. - Policy/geopolitical context: The re-emergence follows funding cuts by the Department of Government Efficiency (DOGE) that slashed US funding for a monitoring and containment project in Central America, right before the US ended a temporary suspension of cattle imports from Mexico. This allowed livestock to cross the border without the USAID-funded monitoring. industry leaders and agriculture officials (like Texas Agriculture Commissioner Sid Miller) had warned about this. - Trade and containment impacts: - Canada's Food Inspection Agency has barred livestock originating in or passing through Texas within 21 days. - Florida has enacted emergency rules restricting warm-blooded animal imports from infested zones. - USDA is releasing sterile flies, trapping, and implementing a 12-mile quarantine zone around the infected areas. They are building a $750M sterile fly facility in Texas, but it won't be operational until 2027. Let's do a search on the "Bundibugyo Ebola Outbreak" or "Ebola DRC Uganda" to see if there are updates, as there was a prior finding on: `Bundibugyo Ebola Outbreak Nears 600 Cases as Geopolitical Travel Row Escalates Ahead of World Cup` (slug: `bundibugyo-ebola-outbreak-drc-uganda`). Let's see if there are fresh updates since June 10, 2026. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will search for any recent updates on the Bundibugyo Ebola outbreak in DRC/Uganda.

This is a major update! The Bundibugyo Ebola outbreak case counts have risen significantly. Let's look at the numbers. - As of June 11, 2026, Africa CDC announced that there are **708 confirmed cases** and **141 confirmed deaths** (or 689 cases and 139 deaths in DRC, and spread to Uganda with some cases). - Let's fetch the WHO Disease Outbreak News (DON) from June 12/13, 2026, or the Bulrushes / Eastern Mirror Nagaland article to get the exact breakdown of the cases in DRC and Uganda. - Also, Cepheid donated Xpert Hemorrhagic Fever Panel tests, and the U.S. State Department increased its funding by $20 million (bringing total U.S. aid to $220 million, let's verify). Let's fetch the WHO DON or the Bulrushes article. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will fetch the WHO Disease Outbreak News article (item 2026-DON607 or similar) to get the most accurate and official epidemiological breakdown of the Bundibugyo Ebola outbreak in DRC and Uganda.

This is an incredibly rich, primary-source update for the Bundibugyo Ebola outbreak. Let's analyze the new numbers and updates: - Cumulative confirmed cases: **695** (676 in the DRC, 19 in Uganda). - Cumulative confirmed deaths: **138** (136 in the DRC, 2 in Uganda). - In the DRC, the case count rose by **161 confirmed cases** and **45 confirmed deaths** since June 8 (the last report), bringing the DRC totals to 676 confirmed cases and 136 deaths (CFR 20.1%). It's concentrated in Ituri Province (93% or 629 cases), especially Bunia (185), Rwampara (137), Mongbwalu (132), and Nyankunde (33). - In Uganda, no new cases have been reported for six days. There are 19 confirmed cases (14 imported, 5 secondary transmission among contacts/health workers) and 2 deaths (plus 1 probable death), concentrated in Kampala and Wakiso districts (Kampala Metropolitan Area). No community transmission has been documented in Uganda. - Clinical trials for therapeutics are being set up. Candidates being considered: - **MBP134** and **REGN3479** for treatment. - **Obeldesivir** for post-exposure prophylaxis. - The protocols have been submitted and are under review by ethics committees and regulatory authorities in both countries. - Risk assessment: Very high in the DRC, high in Uganda, high for countries sharing land borders with them, low for the rest of Africa and globally. Let's check if there are other open watches or threads we can resolve or update. We have: 1. `FDA regulatory filing and decision on Eli Lilly's Foundayo in Type 2 diabetes` (fire_date: 2027-04-30) - too far out. 2. `FDA regulatory filing and decision on Takeda's zasocitinib in plaque psoriasis` (fire_date: 2027-04-30) - too far out. 3. `FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination` (fire_date: 2027-06-30) - too far out. 4. `Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP` (fire_date: 2027-06-30) - too far out. 5. `Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP` (fire_date: 2027-06-30) - too far out. 6. `Eli Lilly SURPASS T1D-1 Phase 3 trial readout in Type 1 Diabetes` (fire_date: 2026-11-30) - too far out. 7. `DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout` (fire_date: 2027-06-30) - too far out. 8. `Alterity Therapeutics ATH434 Phase 3 MSA trial initiation` (fire_date: 2026-12-31) - too far out. 9. `Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision` (fire_date: 2027-06-30) - too far out. 10. `Pfizer berobenatide Phase 3 obesity trial readout` (fire_date: 2027-12-31) - too far out. 11. `Phase 3 trial readout for VGA039 in von Willebrand disease` (fire_date: 2028-12-31) - too far out. 12. `ISS Russian Zvezda module air leaks and repairs` (ongoing) - let's see if there are any updates since June 7, 2026 (the date of the last finding `Space Safety: Persistent Air Leaks Trigger Brief ISS Emergency Shelter Order inside SpaceX Dragon`). Let's search. 13. `FDA regulatory decision on giredestrant in HR+ early-stage breast cancer` (fire_date: 2026-11-30) - too far out. 14. `FDA regulatory decision on bezuclastinib in GIST` (fire_date: 2026-11-30) - too far out. 15. `Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout` - let's search if there are any updates on H5N1 bird flu vaccine or Moderna's trial. 16. `sBLA submission for Zynlonta plus rituximab in r/r DLBCL` (fire_date: 2026-12-31) - too far out. 17. `NHS-Galleri trial cancer mortality data release` (ongoing) - too far out. 18. `NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC)` (fire_date: 2027-02-01) - too far out. 19. `Global Phase 3 trial readouts for ivonescimab (HARMONi studies)` (ongoing) - too far out. 20. `Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines` (ongoing) - let's search if there are any updates on these vaccines (CEPI-supported candidates from Moderna, Oxford, and IAVI). Let's search for "ISS Russian Zvezda air leaks" or "ISS leaks June 2026" to see if there is any new development since June 7, 2026. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will search for any fresh updates regarding the ISS Russian Zvezda module leaks and repairs.

Ah, the search budget is spent. That is perfectly fine, we have an incredible amount of detailed, high-quality, and fresh information to write notes about! Let's review the findings we want to write or update: 1. **New World Screwworm (NWS) Outbreak in the US Southwest**: This is a brand-new, highly consequential outbreak and veterinary public health story. (No prior finding exists for screwworm, so we will mint a new slug: `new-world-screwworm-us-outbreak-2026`). 2. **Bundibugyo Ebola Outbreak (DRC/Uganda)**: We have a prior finding (`bundibugyo-ebola-outbreak-drc-uganda`). We should update it because the cases have jumped significantly (to 695 confirmed cases, 138 deaths) and there are new diagnostic shipments, increased US funding ($20M more), and clinical trials of therapeutics (MBP134, REGN3479, and obeldesivir) being submitted for regulatory review in both countries. 3. **FDA Accelerated Approval of Sanofi's Tzield in Stage 3 Type 1 Diabetes**: This is a brand-new regulatory milestone (on June 12, 2026). Previously, Tzield was approved to delay Stage 3 in Stage 2 patients. Now it is approved as the first disease-modifying therapy for patients *recently diagnosed* with Stage 3 T1D to delay decline in endogenous insulin, based on the PROTECT Phase 3 study. (Prior finding `obesity-incretin-pipeline-readouts` captures GLP-1s, and `roche-acmopatide-ct868-type1-diabetes-halt` catches Roche's T1D drug. But Tzield's new indication is a distinct, major milestone. Let's create a stable slug for Tzield: `sanofi-tzield-stage3-t1d-fda-approval`). 4. **FDA Approval of AstraZeneca's Truqap (capivasertib) in PTEN-Deficient mHSPC**: On June 12, 2026, the FDA approved Truqap in combination with abiraterone and prednisone for adult patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, based on the CAPItello-281 Phase 3 study. This is a first-in-class AKT inhibitor moving into a new indication. Let's create a stable slug: `astrazeneca-truqap-pten-deficient-prostate-cancer`. 5. **FDA Approval of Bemotrizinol (Parsol Shield)**: The FDA approved bemotrizinol, the first new sunscreen chemical filter in the US in over 20 years, triggering an 18-month marketing exclusivity for DSM-Firmenich. This is a huge milestone for US sun care under the "Make America Healthy Again" (MAHA) initiative. Let's create a stable slug: `fda-approval-bemotrizinol-sunscreen-filter`. Wait, the instructions say: - "Call `write_note` — ONE note per theme, never a combined write-up." - "For each distinct theme or story worth persisting, call `write_note` — ONE note per theme, never a combined write-up." - "Body shape: `# <Title for this finding>` ... `## Sources` ... No YAML frontmatter." - "Slugs are stable identities, not per-cycle labels — this is what makes findings a living document. Name a slug for the DURABLE SUBJECT it tracks... Before you write, scan your prior findings (the injected block + `read_notes`) for the slug that already owns this subject and reuse it." Let's check if we have any prior findings we can reuse: - For Bundibugyo Ebola outbreak, we have `bundibugyo-ebola-outbreak-drc-uganda`. We will reuse this slug and update the note in place. - For the others, they are brand-new subjects, so we will mint fresh, durable, subject-focused slugs: - `new-world-screwworm-us-outbreak-2026` -> wait, "never the transient story-of-the-day (`sp-h-c99-library`, `q3-earnings-beat`), which can never recur." So let's use a durable subject slug like `new-world-screwworm-us-outbreak`. - For Tzield: `sanofi-tzield-type1-diabetes`. - For Truqap: `astrazeneca-truqap-prostate-cancer`. - For Bemotrizinol: `fda-sunscreen-filter-approvals` or `bemotrizinol-sunscreen-fda-approval`. Let's use `bemotrizinol-sunscreen-fda-approval`. Let's double check if we have any other threads to resolve. Wait, let's look at the threads: - `Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines` (ongoing). We can't resolve this yet, but we can update our findings. - Wait, do we have a watch for Tzield or Truqap? Let's check the threads list. There are no threads/watches specifically tracking Tzield's Stage 3 approval or Truqap's mHSPC approval. Wait, there is a watch: `FDA regulatory filing and decision on Eli Lilly's Foundayo in Type 2 diabetes` (one_shot, fire_date: 2027-04-30). And `Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP` (one_shot, fire_date: 2027-06-30). And `ISS Russian Zvezda module air leaks and repairs` (ongoing). Wait, the ISS leak had a major event on June 5, 2026, which was covered in the last cycle's note `Space Safety: Persistent Air Leaks Trigger Brief ISS Emergency Shelter Order inside SpaceX Dragon` (slug: `iss-air-leak-dragon-shelter-june-2026`). In this cycle, the search results show that the leak was investigated further and astronauts were put on evacuation alert, but there isn't a completely new separate event or resolution yet. Since it's a minor update to the ongoing situation, we can focus on the major new approvals and the Ebola outbreak. Let's write the notes. First, let's update the Bundibugyo Ebola outbreak note (`bundibugyo-ebola-outbreak-drc-uganda`). Let's see the previous preview of `bundibugyo-ebola-outbreak-drc-uganda`: "The severe outbreak of Ebola caused by the rare Bundibugyo ebolavirus (BDBV) strain in the Democratic Republic of Congo (DRC) and Uganda continues to escalate rapidly. As of June 10, 2026, the DRC..." Let's write a comprehensive, updated finding under the slug `bundibugyo-ebola-outbreak-drc-uganda`. Let's draft the note for `bundibugyo-ebola-outbreak-drc-uganda`: - Title: Bundibugyo Ebola Outbreak Exceeds 690 Cases as US and WHO Mobilize Therapeutic Clinical Trials - Content: Incorporate the latest numbers from the WHO DON (June 13, 2026): 695 confirmed cases (676 in DRC, 19 in Uganda) and 138 confirmed deaths (136 in DRC, 2 in Uganda). Concisely explain the geographical spread (Ituri Province, North/South Kivu in DRC; Kampala/Wakiso in Uganda). Mention the upcoming clinical trials for therapeutics (MBP134, REGN3479, and obeldesivir as post-exposure prophylaxis), whose protocols are under review by ethics and regulatory authorities. Also mention the $20 million additional funding from the US State Department and Cepheid's donation of Xpert Hemorrhagic Fever Panel tests. Let's draft the second note for the New World Screwworm outbreak: - Slug: `new-world-screwworm-us-outbreak` - Title: New World Screwworm Re-emerges in US Southwest, Triggering FDA Emergency Authorization and Trade Restrictions - Content: Explain that a flesh-eating parasite (*Cochliomyia hominivorax*), eradicated in the 1960s, has re-emerged in Texas and New Mexico with 9 confirmed cases (cattle, goats, dog) since May 2026. The FDA issued an Emergency Use Authorization (EUA) on June 11, 2026, for generic **nitenpyram** tablets (normally for fleas) to treat infested dogs and cats. Note the political/policy context: the return follows DOGE funding cuts to a monitoring project in Central America just before cattle imports from Mexico resumed. Canada has barred livestock from Texas, and Florida restricted imports from infected zones. Let's draft the third note for Tzield (teplizumab): - Slug: `sanofi-tzield-type1-diabetes` - Title: FDA Grants Accelerated Approval to Sanofi’s Tzield for Newly Diagnosed Stage 3 Type 1 Diabetes - Content: On June 12, 2026, the FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) to delay the decline of endogenous insulin production in pediatric patients aged 8 to 17 with newly diagnosed Stage 3 (clinical) Type 1 diabetes. This represents the first disease-modifying therapy approved for clinical-stage T1D, targeting the early post-diagnosis "honeymoon" window to preserve beta-cell function. The approval was supported by the Phase 3 PROTECT trial, which demonstrated a significant slowing of C-peptide decline compared to placebo (p<0.001). The confirmatory Phase 3 trial, BETA-PRESERVE (NCT07088068), is currently enrolling. Note the regulatory drama: CDER delayed the decision past its April goal date due to internal disagreements involving former CDER director Tracy Beth Høeg. Let's draft the fourth note for Truqap (capivasertib): - Slug: `astrazeneca-truqap-prostate-cancer` - Title: FDA Approves AstraZeneca’s Truqap Combination for PTEN-Deficient metastatic Prostate Cancer - Content: On June 12, 2026, the FDA approved AstraZeneca's Truqap (capivasertib) in combination with abiraterone and prednisone for adult patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC, or mAPMN/S). This represents the first targeted treatment for this aggressive form of prostate cancer, which affects roughly 1 in 4 mHSPC patients. The approval was based on the Phase 3 CAPItello-281 trial, which showed a statistically significant 19% reduction in the risk of radiographic disease progression or death (HR 0.81, p=0.034) and a median rPFS improvement of 7.5 months (33.2 months vs 25.7 months). Let's draft the fifth note for Bemotrizinol: - Slug: `bemotrizinol-sunscreen-fda-approval` - Title: FDA Approves Bemotrizinol as First New Chemical Sunscreen Ingredient in Over 20 Years - Content: On June 9, 2026, the FDA approved bemotrizinol (BEMT, brand name Parsol Shield by DSM-Firmenich), marking the first new chemical UV filter approved in the United States in over two decades. Widely used in Europe and Asia, bemotrizinol is highly photostable and provides robust broad-spectrum UVA and UVB protection without being easily absorbed into the bloodstream. The approval grants DSM-Firmenich an 18-month marketing exclusivity in the US and aligns with the administration's "Make America Healthy Again" (MAHA) strategy to modernize over-the-counter sunscreen regulations. Let's execute these `write_note` calls! Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." First, I will write the updated note on the Bundibugyo Ebola outbreak.

I will now write the note on the New World Screwworm outbreak in the US Southwest. This is a newly emerged biological threat with substantial agricultural and public health policy implications. Let's write under the slug `new-world-screwworm-us-outbreak`. Let's perform the tool call.

Next, I will write the note on the FDA's accelerated approval of Sanofi's Tzield for newly diagnosed Stage 3 Type 1 diabetes. This is a massive milestone, as it's the first disease-modifying therapy for patients who have already progressed to clinical-stage disease, allowing them to preserve beta-cell function during the early post-diagnosis period. I'll use the slug `sanofi-tzield-type1-diabetes`. Let's perform the tool call.

Next, I will write the note on the FDA approval of AstraZeneca's Truqap (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer. This is a first-in-class targeted AKT inhibitor moving into a new indication. I'll use the slug `astrazeneca-truqap-prostate-cancer`. Let's perform the tool call.

Next, I will write the note on the FDA approval of bemotrizinol, the first new sunscreen chemical filter approved in the United States in over 20 years, under the slug `bemotrizinol-sunscreen-fda-approval`. Let's perform the tool call.

All the findings have been successfully written and are grounded in concrete evidence with verbatim quotes and primary-source links. Let's check if there are any threads we can resolve or if we need to record any new watches or threads. Wait! We have several open threads/watches. Let's see: 1. `Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines` (ongoing). We updated the ebola outbreak but did not initiate a clinical trial for vaccines yet. We heard about Cepheid's diagnostic donation and U.S. State Dept funding, and clinical trials for *therapeutics* (MBP134, REGN3479, and obeldesivir) are being set up. The vaccine candidates (Moderna's mRNA, Oxford's ChAdOx1, and IAVI's rVSV) are still ongoing under watch. So we do not resolve this thread. 2. `FDA regulatory filing and decision on Eli Lilly's Foundayo in Type 2 diabetes` (one_shot, fire_date: 2027-04-30). 3. `FDA regulatory filing and decision on Takeda's zasocitinib in plaque psoriasis` (one_shot, fire_date: 2027-04-30). 4. `FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination` (one_shot, fire_date: 2027-06-30). 5. `Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP` (one_shot, fire_date: 2027-06-30). 6. `Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP` (one_shot, fire_date: 2027-06-30). 7. `Eli Lilly SURPASS T1D-1 Phase 3 trial readout in Type 1 Diabetes` (one_shot, fire_date: 2026-11-30). 8. `DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout` (one_shot, fire_date: 2027-06-30). 9. `Alterity Therapeutics ATH434 Phase 3 MSA trial initiation` (one_shot, fire_date: 2026-12-31). 10. `Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision` (one_shot, fire_date: 2027-06-30). 11. `Pfizer berobenatide Phase 3 obesity trial readout` (one_shot, fire_date: 2027-12-31). 12. `Phase 3 trial readout for VGA039 in von Willebrand disease` (one_shot, fire_date: 2028-12-31). 13. `ISS Russian Zvezda module air leaks and repairs` (ongoing). 14. `FDA regulatory decision on giredestrant in HR+ early-stage breast cancer` (one_shot, fire_date: 2026-11-30). 15. `FDA regulatory decision on bezuclastinib in GIST` (one_shot, fire_date: 2026-11-30). 16. `Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout` (one_shot). 17. `sBLA submission for Zynlonta plus rituximab in r/r DLBCL` (one_shot, fire_date: 2026-12-31). 18. `NHS-Galleri trial cancer mortality data release` (ongoing). 19. `NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC)` (one_shot, fire_date: 2027-02-01). 20. `Global Phase 3 trial readouts for ivonescimab (HARMONi studies)` (ongoing). Wait! Let's record a watch for the new clinical trial for Tzield: BETA-PRESERVE (NCT07088068), which is the confirmatory study for Tzield's accelerated approval in Stage 3 Type 1 diabetes. Let's see: `record_watch` is perfect for this! We can track the Phase 3 BETA-PRESERVE trial readout. Let's set a watch for BETA-PRESERVE. Let's think of a realistic fire date. Usually, Phase 3 trials in newly diagnosed T1D take a couple of years. Let's set it for 2028-12-31 or 2029. Let's make it a `one_shot` with a fire date of `2029-12-31T00:00:00Z` or `2028-12-31T00:00:00Z`. Let's use `2028-12-31T00:00:00Z`. Let's also record a watch for the New World Screwworm outbreak. Since there's an ongoing effort to contain it, and the new sterile fly facility in Texas is expected to be operational in 2027, we can set a watch for the operational launch of the USDA's $750 million sterile fly facility in Texas. Let's make it `one_shot` with a fire date of `2027-12-31T00:00:00Z`. Wait, let's look at the parameters for `record_watch`: `topic_id`, `cycle_id`, `title`, `cardinality`, `watch_type`, `description`, `entity`, `fire_date`, `metric`, `op`, `threshold`, `note`. Let's perform the tool call to record these watches. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will record a watch to monitor the Phase 3 BETA-PRESERVE confirmatory study for Tzield in Stage 3 Type 1 diabetes.

I will also record a watch to monitor the operational status of the USDA's $750 million sterile fly production facility in Texas, which is critical for the long-term containment of the New World screwworm outbreak. Let's perform the tool call.

Now, let's call `finish_cycle` to complete this research cycle, as required by the instructions. Remember: "State intent before tool calls, but NEVER predict or claim results before receiving them." I will call `finish_cycle` to conclude the current research cycle.

I have successfully completed the research cycle for this topic. Here is a summary of the findings and updates recorded during this cycle: ### 1. New World Screwworm Re-emerges in US Southwest * **Slug:** `new-world-screwworm-us-outbreak` * **Finding:** The New World screwworm (*Cochliomyia hominivorax*), a highly destructive flesh-eating parasite eradicated in the 1960s, has re-emerged in the U.S. Southwest (Texas and New Mexico), with nine cases confirmed since May 2026. * **Veterinary Action:** On June 11, 2026, the FDA issued an Emergency Use Authorization (EUA) for generic **nitenpyram** tablets (normally used for fleas) to treat infested dogs and cats. * **Policy & Trade Fallout:** The outbreak has sparked political controversy due to recent DOGE-led funding cuts to Central American monitoring programs right before cattle imports from Mexico resumed. Canada has barred livestock from Texas, and Florida has restricted imports from infested zones. ### 2. Bundibugyo Ebola Outbreak Exceeds 690 Cases * **Slug:** `bundibugyo-ebola-outbreak-drc-uganda` (Updated) * **Finding:** The outbreak has reached 695 confirmed cases and 138 confirmed deaths across the DRC and Uganda. It remains heavily concentrated in the DRC's Ituri Province (629 cases). * **Clinical Trials & Aid:** The WHO, Africa CDC, and local authorities are preparing clinical trials evaluating **MBP134** and **REGN3479** for treatment, and **obeldesivir** for post-exposure prophylaxis. The U.S. State Department increased its response funding by $20 million (bringing total aid to $220 million), and Cepheid donated Xpert Hemorrhagic Fever Panel tests. ### 3. FDA Grants Accelerated Approval to Sanofi’s Tzield in Stage 3 T1D * **Slug:** `sanofi-tzield-type1-diabetes` * **Finding:** On June 12, 2026, the FDA approved Sanofi's Tzield (teplizumab-mzwv) under the accelerated approval pathway to delay the decline of endogenous insulin in pediatric patients (aged 8–17) with newly diagnosed Stage 3 (clinical) Type 1 diabetes. * **Clinical Basis:** Supported by the Phase 3 PROTECT study showing a statistically significant slowing of C-peptide decline (p<0.001). The confirmatory Phase 3 trial, **BETA-PRESERVE** (NCT07088068), is currently enrolling. * **Regulatory Context:** The approval was delayed past its April goal date due to internal FDA disagreements involving former CDER Director Tracy Beth Høeg. ### 4. FDA Approves AstraZeneca’s Truqap Combination in Prostate Cancer * **Slug:** `astrazeneca-truqap-prostate-cancer` * **Finding:** On June 12, 2026, the FDA approved AstraZeneca's Truqap (capivasertib) in combination with abiraterone and prednisone as the first targeted treatment for adult patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC, or mAPMN/S). * **Clinical Basis:** Supported by the Phase 3 **CAPItello-281** trial, demonstrating a 19% reduction in the risk of radiographic disease progression or death (HR 0.81, p=0.034) and a median rPFS improvement of 7.5 months (33.2 months vs 25.7 months). ### 5. FDA Approves Bemotrizinol as First New Chemical Sunscreen Filter in 20 Years * **Slug:** `bemotrizinol-sunscreen-fda-approval` * **Finding:** On June 9, 2026, the FDA approved bemotrizinol (BEMT, brand name **Parsol Shield** by DSM-Firmenich), marking the first new chemical UV filter approved in the U.S. in over 20 years. * **Key Benefits:** Highly photostable, provides robust broad-spectrum UVA and UVB protection without being easily absorbed into the bloodstream (unlike older chemicals like oxybenzone). * **Market Impact:** Grants DSM-Firmenich an 18-month marketing exclusivity in the U.S. and aligns with the administration's "Make America Healthy Again" (MAHA) initiative to modernize over-the-counter sunscreen regulations. ### Recorded Watches 1. **Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D** (One-shot, targeted fire date: December 31, 2028). 2. **USDA $750M sterile screwworm fly facility operational launch in Texas** (One-shot, targeted fire date: December 31, 2027).